Estrogen replacement in female lung cancer during gefitinib therapy

5Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Estrogen receptor (ER) has been detected in some specimens of lung cancer. Estrogen has an effect on the growth of lung cancer cell lines. An inverse relationship between ER and epithelial growth factor receptor (EGFR) was reported in pre-clinical data. A 70-year-old female with lung adenocarcinoma, who achieved a partial response by gefitinib, underwent estrogen replacement for menopause-associated symptoms during gefinitib therapy. Lung nodules enlarged with 1-month estrogen use and regressed 6 weeks after the end of estrogen therapy. To our knowledge, this is the first case report regarding the interaction between estrogen and EGFR inhibitors. © The Author (2009). Published by Oxford University Press. All rights reserved.

Cite

CITATION STYLE

APA

Wang, P. H., Wang, H. C., & Tsai, C. C. (2009). Estrogen replacement in female lung cancer during gefitinib therapy. Japanese Journal of Clinical Oncology, 39(12), 829–832. https://doi.org/10.1093/jjco/hyp096

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free